Guggenheim analyst Debjit Chattopadhyay raised the firm’s price target on NewAmsterdam Pharma (NAMS) to $41 from $35 and keeps a Buy rating on ...

NewAmsterdam's financial stability and potential $100 billion market size highlight significant upside, but market skepticism ...

NewAmsterdam Pharma's obicetrapib lowers LDL-C in Phase 3 trials, showing promise as a CETP inhibitor. Read more on NAMS ...

We recently published a list of 10 Oversold Biotech Stocks to Buy Now. In this article, we are going to take a look at where ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on NewAmsterdam Pharma Company (NAMS – Research ...

Shares of NewAmsterdam Pharma stock opened at $21.00 on Thursday. NewAmsterdam Pharma has a fifty-two week low of $15.19 and a fifty-two week high of $27.29. The firm has a fifty day moving ...

NASDAQ:NAMS opened at $21.00 on Thursday. NewAmsterdam Pharma has a twelve month low of $15.19 and a twelve month high of $27.29. The business has a 50 day moving average price of $22.55 and a two ...

NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical ...

Shareholders of NewAmsterdam Pharma Company N.V. ( NASDAQ:NAMS ) will be pleased this week, given that the stock ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

December 31, 2024 -- NAARDEN, the Netherlands and MIAMI, Feb. 26, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam” or the "Company”), a late-stage, clinical ...